Breast Cancer Clinical Trial

Clinical Trial Finder Breast Cancer Trials

Observational Study of Bone Complications in People With Post-menopausal Breast Cancer Who Have Stopped Treatment With Denosumab and Aromatase Inhibitors

Summary

The purpose of this study to gather information about changes in the bones after stopping treatment with aromatase inhibitor/AI and denosumab. The study team will collect information from 5 standard clinic visits over the course of 24 months. The information will include information about participant health assessments, blood test results, and imaging results. After 24 months, participation in this study will be complete.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Women with confirmed diagnosis of breast cancer
Participant must be post-menopausal, defined as last menstrual cycle at least 12 months prior to enrollment
Received at least 2 doses of denosumab and then discontinued therapy
Discontinued AI prior to or within 6 months of last denosumab injection
Patients must be 18 years of age or olde

Exclusion Criteria:

Patients with history of osteoporosis prior to starting denosumab, based on previous dual-energy X-ray absorptiometry (DEXA) scan;
Patients with history of insufficiency fracture.
Patients who continue treatment with a different bone modifying agent (i.e oral or intravenous bisphosphonates) after discontinuation of denosumab
Patients on chronic low-dose glucosteroids.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 7 Locations for this study

See Locations Near You

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge New Jersey, 07920, United States More Info